title: The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function.
abstract: The ADP-ribosyltransferase (ADPRT) gene encodes a zinc-finger DNA-binding protein, poly(ADP-ribose) polymerase-1 (PARP-1), that modifies various nuclear proteins by poly(ADP-ribosyl)ation and functions as a key enzyme in the base excision repair pathway. We have conducted two studies to test whether an amino acid substitution variant, ADPRT V762A (T2444C), is associated with prostate cancer (CaP) risk and decreased enzyme function. The first study used genomic DNA samples from an ongoing, clinic-based case-control study (488 cases and 524 controls) to show that a higher percentage of the CaP cases carried the ADPRT 762 AA genotype than controls (4% versus 2%). In Caucasians, the AA genotype was significantly associated with increased CaP risk [odds ratio (OR), 2.65; 95% confidence interval (CI), 1.08-6.49], and the VA genotype was associated with a slight but not significantly increased CaP risk (OR, 1.18; 95% CI, 0.85-1.64) using VV as the referent group after adjustment for age, benign prostatic hyperplasia, and family history. Furthermore, this association was stronger in younger (<65) men (OR, 4.77; 95% CI, 1.01-22.44) than older (> or =65) men (OR, 1.78; 95% CI, 0.55-5.82). The second study used freshly isolated peripheral lymphocytes from 354 cancer-free subjects to demonstrate that the ADPRT 762 A allele contributed to significantly lower adenosine diphosphate ribosyl transferase (ADPRT)/PARP-1 activities in response to H2O2 in a gene dosage-dependent manner (P < 0.0001, test for linear trend). The PARP-1 activities (mean +/- SD dpm/10(6) cells) were 18,554 +/- 9,070 (n=257), 14,847 +/- 7,082 (n=86), and 12,155 +/- 6,334 (n=11) for VV, VA, and AA genotypes, respectively. This study is the first to provide evidence that the ADPRT V762A-genetic variant contributes to CaP susceptibility and altered ADPRT/PARP-1 enzyme function in response to oxidative damage.
authors.affiliation: Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, 27157, USA.
authors.forename: Kristin L
authors.initials: KL
authors.lastname: Lockett
authors.forename: M Craig
authors.initials: MC
authors.lastname: Hall
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Xu
authors.forename: S Lilly
authors.initials: SL
authors.lastname: Zheng
authors.forename: Marianne
authors.initials: M
authors.lastname: Berwick
authors.forename: Shu-Chun
authors.initials: SC
authors.lastname: Chuang
authors.forename: Peter E
authors.initials: PE
authors.lastname: Clark
authors.forename: Scott D
authors.initials: SD
authors.lastname: Cramer
authors.forename: Kurt
authors.initials: K
authors.lastname: Lohman
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Hu
mesh_terms: D036002:ADP Ribose Transferases / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism; D000368:Aged; D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000235:genetics*
chemical_list: D036002:ADP Ribose Transferases; D011065:Poly(ADP-ribose) Polymerases